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ABSTRACT 
Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much 
more in common with germinal-centre derived B-cell NHL than classical HL. Management of NLPHL 
remains controversial. In a 14-year multi-centre series, 69 cases were analysed; median follow-up 
was 53 months (range 11-165.) B symptoms were present in only 4.3% of patients. 81.1% of patients 
had stage I/II disease. Treatment was with radiotherapy (53.6 %), chemotherapy (21.7%), combined 
modality (17.4%) and observation (7.2%.) 10.1% of patients relapsed and 2.9% of patients developed 
high-grade transformation to DLBCL.  All relapses and transformations were salvageable. No patient 
died of their disease. The 5 yr relapse-free survival was 96.7%, transformation-free survival 98.4% 
and overall survival 100%. We conclude that NLPHL behaves as a distinct clinical entity, often 
presenting at early stage without risk factors. It has an excellent outcome. It may be possible to 
reduce intensity of therapy in NLPHL without affecting OS.  
 
Word Count: 148 words 
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INTRODUCTION 
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) comprises ~5% of all Hodgkin 
lymphoma. Clinically and biologically, NLPHL has more in common with germinal-centre derived B-
cell non-Hodgkin lymphomas (NHLs) than classical Hodgkin Lymphoma (cHL) and clinically is 
characterised by male predominance, early stage disease, excellent response to treatment and good 
outcome. Late relapses and transformation to high-grade non-Hodgkin lymphoma (NHL) are 
recognised. Classical HL is characterised by a loss of the B-cell programme and expression patterns. 
In contrast, the cancer cell in NLPHL, the LP cell1 (formerly known as the “popcorn” or lymphocytic & 
histiocytic cell) expresses B cell markers, more in keeping with NHL, including CD20, CD79, PAX5, 
OCT2 and BOB1.2 Gene expression profiling demonstrates a striking similarity to the patterns of 
expression seen in T-cell rich B-NHL.3 There is a recognised risk of transformation from NLPHL to 
high-grade NHL, particularly diffuse large B-cell NHL (DLBCL4). This risk of transformation, often long 
after the initial diagnosis, has been confirmed in previous studies.5-7   
 
Previous retrospective studies have examined the presentation of NLPHL8-10, however, due to its 
rarity and low incidence of events, there have been no published prospective randomised controlled 
trials in this area, outwith the context of NLPHL cases included in larger cHL trials. As a result, there 
is widespread variation worldwide in treatment of this condition. Such variation makes comparison of 
outcome data between studies challenging. On the basis of this work, however, there is a growing 
feeling that NLPHL, particularly limited stage (IA) disease, may be treated less intensively than cHL. 
For the substantial remainder of patients, many current treatment protocols recommend management 
as for cHL (with chemotherapy and/or radiotherapy.)11 It is being increasingly recognised that late 
toxicity with such treatments is substantial; excess risk of second cancers and cardiovascular disease 
continues to rise long after treatment and even 30 years after diagnosis, HL patients continue to have 
an elevated risk of death from all causes.12 In spite of this, some groups argue for treatment 
intensification8,13 reporting improved responses, without improvements in overall survival.  
 
The aim of this study is firstly to examine the clinical features at presentation of this disease, to 
observe whether NLPHL represents a distinct group. Secondly, the outcome of patients will be 
examined to assess optimal approaches to management. 
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MATERIALS AND METHODS 
 
Case Ascertainment 
Cases were identified through registration with the West of Scotland Cancer Network lymphoma 
database. The population of the area covered in the study is 2.6 million.14  A diagnosis of NLPHL was 
made in 71 patients (adults and children) between 01/01/97 – 31/10/10. Diagnosis was confirmed by 
cross-referencing with pathology reports in all cases. Most cases had pathology reviewed in the 
context of reference review to an expert haemato-pathologist and discussion at regional pathology 
team meetings. On pathological review, two patients were found to have T-cell rich DLBCL at time of 
initial diagnosis, and were excluded from the analysis. Thus, a total of 69 patients were included in the 
analysis. Eight of a total of nine re-presentations were biopsied (88%). Cases were censored as of 
31/10/10. Eight patients (11.2%) were unavailable for analysis at the census date (“lost to follow up”.) 
As this was a retrospective non-interventional study, complete case analysis was used and these 
patients were censored at the date when last seen. The median follow-up time was 53 months (range 
11-165 months). 
 
Clinical Characteristics, Management And Outcomes 
Data was obtained using direct case-note review, using a standard form. The following baseline 
clinical variables were recorded: sex, age at diagnosis, date of diagnosis, co-morbidity, duration of 
symptoms, presence or absence of B-symptoms, Ann Arbor Stage, involved nodal sites, other site of 
disease (pulmonary, spleen, bone marrow, other extranodal),  the presence or absence of EORTC 
risk-factors for early stage disease: (mediastinal disease > 0.33 intra-thoracic diameter at T5/6, age ≥ 
50 years, ESR > 50mm/h, ≥ 4 nodal areas)15, Hasenclever score for advanced stage disease (serum 
albumin <4g/dl, haemoglobin <10.5g/dl, male sex, stage IV disease, age ≥ 45, white cell count ≥ 
15000/mm3, lymphocyte count <600/mm3 or 8% of total white count 16), supra-diaphragmatic disease 
only, axial disease only. Staging at diagnosis employed computed tomography (CT) scanning, and, 
when it became available, positron emission tomography-computed tomography (PET-CT) scanning. 
PET-CT scanning was in routine use in the region after 2008. All patients with advanced disease 
underwent bone marrow examination. The decision to examine bone marrow in early stage disease 
was at the discretion of the individual clinician. All patients were managed by individual consultant 
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haemato-oncologists who chose the treatment. All had access to a regional multi-disciplinary team 
meeting by video-conference, where cases could be discussed. From 2005, all had access to the 
local Clinical Management Guideline which recommended involved field radiotherapy only for stage IA 
NLPHL, and standard treatment as per classical HL for all other cases. Management of disease was 
recorded as excision only (observation only or “watch and wait”), chemotherapy, radiotherapy or 
combined modality (chemotherapy and radiotherapy.) For those patients who received chemotherapy, 
the regime used and number of cycles given was recorded. For those patients who received 
radiotherapy, the site irradiated, dose and fractionation were recorded. Any toxicity or complication of 
therapy was recorded. Clinical response to therapy was assessed at end of treatment using CT 
scanning, and, when it became available and was appropriate, PET-CT scanning. For those patients 
who re-presented, progressions were classed as either relapse of NLPHL or transformation to high-
grade non-Hodgkin lymphoma. Subsequent therapy was recorded, as was response. For those 
patients who died, cause of death was recorded.  
 
Definitions 
Responses were classified according to the criteria of Cheson et al.17 Complete response (CR) was 
defined as complete disappearance of all detectable clinical evidence of disease and disease-related 
symptoms if present before therapy, or, in the case of patients in whom the PET scan was positive 
before therapy, a post-treatment residual mass of any size was permitted as long as it was PET 
negative. Partial response (PR) was defined as at least a 50% decrease in sum of the product of the 
diameters (SPD) of up to six of the largest dominant nodes or nodal masses, with the additional 
criteria as defined above. Stable disease was defined as when a patient failed to attain the criteria 
needed for a CR or PR, but did not fulfil those for progressive disease. Progressive disease (PD) was 
defined as any new lesion or increase in SPD by> 50% of previously involved sites from the nadir. 
Overall survival (OS) was measured from the date of diagnosis to date of last follow-up or death. 
Relapse-free survival (RFS) is defined as time from date of diagnosis to either progression, relapse of 
the initial NLPHL diagnosis only, or death from any cause. Transformation-free survival (TFS) was 
defined as time from date of diagnosis to transformation to high-grade NHL, or death from any cause. 
Event-free survival (EFS) is defined as time of diagnosis to progression, relapse or high-grade 
transformation, or death from any cause. Survival from relapse and progression were defined as from 
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date of diagnosis of the relapse or transformation to date of last follow-up or death. Patients who died 
with no evidence of progression or event as defined above were censored at date of death. Early 
stage disease was defined as clinical stage I and IIA, and no bulky disease (see below.) Advanced 
stage disease was defined as clinical stage IIB, III and IV or any with bulk disease. Bulk disease was 
defined as nodal mass>10cm or mediastinal mass>0.33 of intra-thoracic diameter at T5/6. Comparing 
tumour volume in this cohort is impossible due to the differences in radiological reporting and volume 
measurements not becoming standard until more recently. For those patients without bulk disease by 
the conventional definition above, we took any nodal mass >2cm as an arbitrary surrogate of higher 
volume disease, to allow comparison of outcome by tumour bulk between patients. 
 
Statistics 
Data was analysed using SPSS software, version 15.0 (IBM Corporation, Somers, NY USA.) 
Standard descriptive statistical analysis was performed. For crude-association analysis, data were 
analysed using the chi-square test. Survival analyses were calculated according using the Kaplan-
Meier method, and presented as either survival curves or hazard curves. Analyses of OS, RFS, TFS 
and EFS using Cox regression were performed to assess any factors associated with these 
measures. Binary logistic regression was used to perform multivariate analysis of the same.  
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RESULTS 
Patient Characteristics 
The main characteristics of the 69 patients are given in table I. The median age of patients was 39.0 
years (range 11-79) and the majority (69.6%) were male. Three children were included in the cohort, 
diagnosed at ages 11, 12 and 14 years. Eighty-one percent of patients presented with stage I or II 
disease. Most patients presented with localised peripheral lymphadenopathy. Lymphadenopathy had 
been present for a median of 6 months prior to diagnosis, and this did not correlate with disease stage 
at presentation. Only 3 patients (4.3%) presented with B-symptoms (one clinical stage II, two stage 
III.) The distribution of patients’ disease is given in table II. Of note, in 50 patients (72.5%) disease 
was confined supra-diaphragmatically.  Only 14 patients (20.3%) had axial disease (mediastinal or 
abdominal.) Fifty-five patients (79.7 %) had early stage disease (stage IA or IIA) and of these, none 
had risk factors as defined by the EORTC (see methods, above.) Fourteen patients (20.3 %) had 
advanced stage disease (Stage IB, IIB, III or IV.)  There was a trend to an increased proportion of 
older patients presenting with advanced stage disease (28% of patients >45 years with advanced 
stage disease as compared with 15.8% of patients under the age of 45 years with advanced stage 
disease, although this did not reach statistical significance (p=0.18 by Chi-square test.) The mean 
Hasenclever score for patients with advanced stage disease was 1.57 (range 1-2); age and male sex 
being the most common risk factors present. No patients had bulk disease as per the accepted 
definitions (see methods.) A majority of patients had disease where at least one of their nodal areas 
was >2cm (55.1%, n=38.) PET-CT scans were performed as part of disease staging in 10 patients. 
No patient was up-staged as a result of this, or necessitated a change in therapy. One patient was 
confirmed to have stage IV disease on the PET-CT scan. 
 
Management 
Patients were managed by 46 haemato-oncologists working in the region. Management was decided 
by the treating physician. The first-line management strategy used is given in table III. The most 
frequent strategy was radiotherapy only employed in 37 patients (53.6%). Forty-nine patients (71.0%) 
received radiotherapy as part of their treatment. The mean radiotherapy dose was 30Gy (range 20-
40Gy) delivered most commonly in 15 or 20 fractions. Radiotherapy was delivered as involved field 
radiotherapy in 45/50 cases. Five cases received mantle radiotherapy (four stage II, one stage I); no 
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patient received mantle radiotherapy after the year 2000. Twenty-seven patients (39.1%) received 
chemotherapy, for 15 of whom, it was sole therapy. The chemotherapies employed in first line 
treatment varied. The most frequent chemotherapeutic regimen employed was doxorubicin, 
bleomycin, vinblastine, dacarbazine (ABVD) (in 25 patients.) Number of cycles varied (median 4, 
range 1.5-6.) Eight of the twelve patients who received ABVD as sole therapy received six cycles. 
Other chemotherapeutic regimens employed included: chlorambucil, vincristine, procarbazine, 
etoposide, prednisolone, doxorubicin, vinblastine (ChlVPP/EVA)18 in two patients and ChlVPP/ABVD 
x 3 in one patient being treated on the paediatric UKCCSG HD 2000/02 protocol, which, at the time, 
did not differentiate NLPHL from cHL. 
  
Five patients were managed by observation only following involved node excision; two with stage I 
disease, two with stage II disease and one with stage III disease. Other than lymphadenopathy, all in 
this group were asymptomatic. The presence of significant co-morbidity in two of these patients 
(chronic renal failure in one, and CNS tuberculosis in the other) may have impacted on the decision to 
manage expectantly. In total, 25 of the 69 patients (36.2 %) had some sort of co-morbidity, which may 
have impacted on ability to deliver therapy. The commonest co-morbidities seen were asthma, seen 
in 6%, and hypertension seen in 6%. Other co-morbidities which may have potentially affected 
therapeutic choices included Wolff-Parkinson-White syndrome, alcohol excess, diabetes, ischaemic 
heart disease, aortic incompetence and renal dysfunction. 
 
Response 
Sixty-three of the sixty-four treated patients obtained a CR with first line treatment (98.4%), the other 
one patient obtaining a PR, which remains stable. No patient failed to respond to first line treatment. 
No patient in our cohort had primary progressive disease. Of the five patients managed by 
observation, one developed a transformation to DLBCL at 16 months. The other developed 
progression of his primary disease (asymptomatic increase in size of lymph nodes) at 85 months, but 
is still not requiring therapy, and continues to be managed expectantly. The other three continued to 
have stable disease at a median of 57.0 months from diagnosis. 
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 Complications of therapy 
One of the compelling arguments for treatment reduction in this group of patients is the toxicity of 
therapy. Complications of first line treatment were seen in eighteen patients (28.1% of treated 
patients.) For patients receiving radiotherapy as sole treatment modality, 27 of 37 patients tolerated 
this with no complications. Four patients became hypothyroid. Other toxicities of radiotherapy were 
xerostomia, local discomfort over biopsy/irradiated area, infertility and oesophagitis. For the 29 
patients who received chemotherapy, 18 tolerated it with no complications. Three of the 27 patients 
developed infection, which was the commonest toxicity of chemotherapy. Two patients developed 
respiratory toxicity, both of whom had received bleomycin. Of particular note, one of the paediatric 
patients, a male treated at age 12 with ChlVPP/ABVD x 3, has since been found to be infertile, 
confirmed on sperm analysis. Multivariate analysis by age, treatment modality, clinical stage and co-
morbidity failed to predict who would suffer from treatment associated toxicity. 
 
Outcomes 
Seven patients (10.1%) relapsed (histopathologically confirmed NLPHL in 6 cases) at a mean of 57.7 
months (range 13-121 months.) These relapses occurred in 3 patients with stage I disease, 2 with 
stage II disease, and 1 each with stage III and IV disease. The treatment of the primary disease in 
these cases varied (1 observation only, 3 radiotherapy only, 2 chemotherapy only & 1 combined 
modality therapy.) The majority of relapses were treated with chemotherapy, including one patient 
who received an autologous PBSCT. The treatments of the relapses included: ABVD (for 2 patients 
who had not received chemotherapy before, and 1 who had received 2 cycles as part of combined 
modality first line treatment), splenectomy, IVE and BEAM Auto-PBSCT, and ChlVPP PA(BL)OE (all 
one patient each.) One patient remains asymptomatic and has not yet commenced treatment. One of 
the patients is currently receiving treatment for relapse, but the other 5 are in CR at a median follow-
up of 44.5 months (range 13-121.) In all cases, these relapses were salvageable and there were no 
deaths resulting from relapsed disease. The 2-year relapse-free survival was 96.7%. The 5-year 
relapse free survival was 92%.  
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Two patients (2.9%) went on to develop high grade transformation to DLBCL at 2 and 81 months. 
One patient was treated with 6xR-CHOP whilst the other patient received 3xR-CHOP prior to  
consolidation with DHAPx3, IVEx1 and a BEAM autologous PBSCT. Both patients treated for their 
high grade transformations achieved a CR with treatment. The median survival from transformation 
was 61.5 (range 40-83) months. Both high-grade transformations were salvageable and there were 
no deaths resulting from transformed disease. The 2-year and 5-year transformation-free survival was 
98.4%. When relapses and transformations are taken together, this gives an overall event free 
survival at 2 years of 93.3% and 90.5% at 5 years. Figure 1 demonstrates the Kaplan-Meier plots for 
event-free survival. 
 
In order to assess the efficacy of less-intensive treatment in early stage disease, we analysed the 
outcomes in the 37 (53.6%) of stage I and II patients treated with single-modality radiotherapy. In this 
group, outcomes were excellent with relapse-free survival of 93.9% at 5-years, transformation-free 
survival of 100% at 5 years and overall survival of 100% at 5 years (demonstrated in Figure 2).  
 
Cox regression modelling of relapse-free and transformation free survival by age at diagnosis, clinical 
stage, treatment modality, presence of B symptoms, axial disease or Hasenclever score failed to give 
a model for predicting those patients more likely to relapse.  
 
There were two deaths in this cohort, neither of which was related to the diagnosis of NLPHL, its 
transformation, relapse or treatment (the causes of death for the two patients being trauma in one 
case, and confirmed lung carcinoma 7.5 years after diagnosis in one of the patients who was 
managed by observation only.) The 5-year OS was 100% and disease specific survival was 100%. 
The Kaplan-Meier plot for overall survival is given in Figure 3. 
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DISCUSSION 
Our study adds to the current literature in this area. Accepting the potential limitations of a 
retrospective cohort analysis, we suggest that the strengths of our study are its applicability to current 
oncology practice. As a multi-centre study with management strategies decided by individual 
physicians, this study is representative of practice in many settings. In contrast to recent single 
centre-studies,5,19 our cohort is restricted to cases diagnosed since 1997 which will have been 
managed with modern, accepted diagnostic techniques, treatments and response definitions.  
 
We confirm that NLPHL behaves clinically as a distinct clinical entity. The majority of patients present 
with early stage disease, with localised peripheral lymphadenopathy. The presence of B-symptoms 
was unusual, and most patients had no other risk factors. All patients responded well to primary 
therapy, most attaining a CR.  
 
In our study, there was a 10.1% relapse rate. Relapses and progressive disease continued to occur 
late in the natural history of the disease, with relapses in particular, occurring steadily to more than 10 
years post first-treatment, with no sign in a plateau in the curve. This is in contrast to cHL, where 
much of the relapse risk is early and can be predicted in higher-risk groups of patients. Cox 
regression modelling of relapse-free and transformation free survival in this study failed to give a 
model for predicting those patients more likely to relapse. This is in itself significant, as it suggests 
that the natural history of this disease proceeds regardless at which stage the patient is at when 
diagnosed, or indeed whichever management strategy is taken. Whilst underpowered to detect 
equivalence, there is no evidence in our study to support the proposal that early, more intensive 
therapy, particularly in the form of chemotherapy will be beneficial, as has been suggested by other 
studies.13  Instead, we would argue, that as relapse risk exists is unmodified by stage or first-line 
treatment, a strategy of minimal therapy as and when required will achieve disease control with fewer 
toxicities. In our study, all relapses responded fully to therapy, suggesting no advantage in earlier 
intensification.  
 
Particularly striking in our cohort is the 7.2% of patients managed by observation only (“watch & wait”) 
in whom there was no detectable difference in survival compared with the treated patients. We note 
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that the numbers managed by observation alone are too small to demonstrate statistical significance, 
but our outcomes are in agreement with other studies suggesting that management by resection only 
may be appropriate in selected groups of limited stage patients.20  
 
The majority of patients were able to be treated by involved-field radiotherapy (IFRT) alone, avoiding 
many of the toxicities of extended field radiotherapy or chemotherapy. Previous published studies 
have suggested that for early stage patients, radiotherapy alone may be potentially curative.21 The OS 
of 100% and EFS of 93.9% at 5 years in the stage I and II patients treated with single modality 
radiotherapy in our study would certainly support this approach; although we noted an ongoing risk of 
late relapse in this group. 
 
As has been described in other studies8-10, we found an ongoing risk of evolution to high-grade NHL. 
However, the risk of this was comparatively low (2.9%) and, in contrast to de novo high-grade NHL, 
all cases were salvageable to sustained CRs with therapy. Overall, in our study, NLPHL has an 
excellent outcome and there were no deaths due to lymphoma.  
Some large co-operative study groups are beginning to introduce reduced-intensity treatment options 
for NLPHL. The EURONET paediatric protocol for NLPHL22 is randomising between excision and 
observation in PET negative patients versus low intensity regimens omitting anthracycline. It is 
certainly interesting that the three children treated in our study received what would now be regarded 
as intensive therapy, with significant late toxicity (infertility) in at least one case. Current large multi-
centre studies on-going in the United Kingdom (e.g. NCRI RATHL) specifically exclude NLPHL. Given 
the CD20 positivity of this disease, recent commentators23,24 have suggested the addition of rituximab 
to chemotherapeutic regimes for NLPHL. The rationale for this is logical, the outcomes are good, and 
the suggestion that a putative HL stem cell may be CD20 positive supports this.25 However, in the 
case of NLPHL, the natural history of the disease would support reserving this for those patients with 
relapsed disease, even as an alternative to chemo/radiotherapy.  
 
Our local policy now recommends a first-line “watch and wait” strategy for those stage IA patients who 
are PET negative after excision biopsy, IFRT alone for stage IA and IIA patients, and six cycles of 
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ABVD chemotherapy for patients with stage III and IV disease. Data will continue to be collected. We 
suggest that it may be possible to reduce intensity of therapy in NLPHL without affecting OS, whilst 
substantially reducing the risk of late toxicities of treatment. We would support the development of 
multi-centre randomised controlled studies in this condition to address this hypothesis. 
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Table I: Clinical characteristics of the 69 cases of NLPHL included in the study (note, where 
percentages do not come to 100%, this is due to rounding) 
 
Characteristic Number of Patients (%) 
Male sex 48 (69.6) 
<16 3 (4.3) 
17-29 18 (26.1) 
30-45 23 (33.3) 
45-60 15 (21.7) 
Age Group 
>61 10 (14.5) 
I 35 (50.7) 
II 21 (30.4) 
III 9 (13.0) 
Stage 
IV 4 (5.8) 
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Table II: Distribution of disease by involved region. Note, nodal involvement is not isolated unless 
otherwise specified. 
 
Region Involved Number (%) 
Parotid 3 (4.3) 
Sub-mandibular 4 (5.8) 
Cervical 44 (63.8) 
of which, number with isolated cervical disease only 25 (36.2) 
Axillary 23 (33.3) 
of which, number with isolated axillary disease only 10 (14.5) 
Mediastinal 6 (8.7) 
Inguinal 10 (14.5) 
Abdominal 11 (15.9) 
Bone marrow 3 (4.3) 
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 Table III: First-line treatment of patients by clinical stage (number of patients) 
 
 
 
Stage    (%) 
Observation 
 
Radiotherapy 
Only 
Chemotherapy 
only 
Combined 
Modality 
I           50.7 2 26 1 6 
II          30.4 2 11 3 5 
III         13.0 1 0 8 0 
IV          5.8 0 0 3 1 
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Figure Legends 
 
Figure1: Kaplan-Meier plot of event-free survival (months) by type of progression 
 
Figure 2: Kaplan-Meier plot of event-free survival (months) in all stage I & II patients treated by single 
modality radiotherapy as first-line treatment 
 
Figure 3: Kaplan-Meier plot of overall survival (months) 
 
 
 
